Delaware
|
91-1955323
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
80
Commerce Drive, Allendale, NJ
|
07401
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Large
Accelerated filer o
|
Accelerated
filer o
|
Non-accelerated
filer o
(do
not check if a smaller reporting company)
|
Smaller
reporting company x
|
Item
1.
|
Financial
Statements:
|
|
Condensed
Balance Sheets as of September 30, 2009 (unaudited) and
|
||
December
31, 2008 (audited)
|
4
|
|
Condensed
Statements of Operations for the three and nine months
ended
|
||
September
30, 2009 and 2008 and from August 23, 2000 (inception)
through
|
||
September
30, 2009 (unaudited)
|
5 | |
Condensed
Statements of Cash Flows for the nine months ended
|
||
September
30, 2009 and 2008 and from August 23, 2000 (inception)
through
|
||
September
30, 2009 (unaudited)
|
6 | |
Condensed
Statement of Stockholders’ Equity (Deficit) from August 23, 2000
(inception)
|
||
through
September 30, 2009 (unaudited)
|
7 | |
Notes
to Condensed Financial Statements
|
12 | |
Item
2.
|
Management's
Discussion and Analysis of Financial Condition and Results
|
|
of
Operations
|
19
|
|
Item
3.
|
Qualitative
and Quantitative Disclosures About Market
Risk...............................
|
23 |
Item
4T.
|
Controls
and Procedures
|
23
|
PART
II. OTHER INFORMATION
|
||
Item
1.
|
Legal
Proceedings
|
23
|
Item
1A.
|
Risk
Factors
|
24
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
24
|
Item
3.
|
Defaults
Upon Senior Securities
|
24
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
24
|
Item
5.
|
Other
Information
|
24
|
Item
6.
|
Exhibits
|
24
|
SIGNATURES
|
|
25 |
ARBIOS
SYSTEMS, INC.
|
||||
(A
Development Stage Company)
|
||||
CONDENSED
BALANCE SHEETS
|
Successor
|
Predecessor
|
|||||||
September
30, 2009
|
December
31,
|
|||||||
ASSETS
|
(Unaudited)
|
2008
|
||||||
Current
assets
|
||||||||
Cash
|
$ | 193,815 | $ | 370,686 | ||||
Cash
held in attorney trust
|
270,323 | - | ||||||
Prepaid
expenses
|
- | 21,506 | ||||||
Total
current assets
|
464,138 | 392,192 | ||||||
Receivable
|
- | 200,000 | ||||||
Property
and equipment, net
|
- | 6,177 | ||||||
Investment
|
- | 86,209 | ||||||
Other
assets
|
- | 750 | ||||||
Total
assets
|
$ | 464,138 | $ | 685,328 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT)
|
||||||||
Current
liabilities
|
||||||||
Accounts
payable
|
$ | 470,870 | $ | 194,046 | ||||
Accrued
expenses
|
- | 286,888 | ||||||
Total
current liabilities
|
470,870 | 480,934 | ||||||
Long
term contract obligations
|
- | 150,000 | ||||||
Total
liabilities
|
470,870 | 630,934 | ||||||
Stockholders'
equity (deficit)
|
||||||||
Successor
common stock, $.001 par value; 100,000,000 shares authorized;
50,000,000
|
||||||||
shares
issued and outstanding at September 30, 2009
|
50,000 | - | ||||||
Predecessor
common stock, $.001 par value; 100,000,000 shares
authorized; 25,792,747
|
||||||||
shares
issued and outstanding at December 31, 2008
|
- | 25,792 | ||||||
Additional
paid-in capital
|
143,256 | 21,617,075 | ||||||
Receivable
for stock issuance
|
(199,988 | ) | - | |||||
Deficit
accumulated during the development stage
|
- | (21,588,473 | ) | |||||
Total
stockholders' equity (deficit)
|
(6,732 | ) | 54,394 | |||||
Total
liabilities and stockholders' equity (deficit)
|
$ | 464,138 | $ | 685,328 |
The
accompanying notes are an integral part of these condensed financial
statements.
|
ARBIOS
SYSTEMS, INC.
|
(A
Development Stage Company)
|
CONDENSED
STATEMENTS OF OPERATIONS
|
(Unaudited)
|
Predecessor
|
Predecessor
|
Predecessor
|
Predecessor
|
Predecessor
|
||||||||||||||||
For
the three months ended September 30,
|
For
the nine months ended September 30,
|
Inception
to
|
||||||||||||||||||
2009
|
2008
|
2009
|
2008
|
September
30, 2009
|
||||||||||||||||
Revenues
|
$ | - | $ | - | $ | - | $ | - | $ | 320,966 | ||||||||||
Operating
expenses:
|
||||||||||||||||||||
General
and administrative
|
256,348 | 147,103 | 660,795 | 1,358,718 | 13,902,846 | |||||||||||||||
Research
and development
|
- | 164,350 | - | 1,220,747 | 9,325,632 | |||||||||||||||
Total
operating expenses
|
256,348 | 311,453 | 660,795 | 2,579,465 | 23,228,478 | |||||||||||||||
Operating
loss
|
(256,348 | ) | (311,453 | ) | (660,795 | ) | (2,579,465 | ) | (22,907,512 | ) | ||||||||||
Other
income (expense):
|
||||||||||||||||||||
Loss
from disposition of fixed assets
|
(3,120 | ) | - | (3,120 | ) | - | (3,120 | ) | ||||||||||||
Interest
income
|
- | 3,786 | 229 | 32,264 | 497,748 | |||||||||||||||
Gain
on sale of HepatAssist program, net
|
- | - | 404,863 | |||||||||||||||||
Loss
on investment
|
- | - | (86,209 | ) | - | (86,209 | ) | |||||||||||||
Interest
expense
|
- | - | - | - | (244,138 | ) | ||||||||||||||
Total
other income (expense)
|
(3,120 | ) | 3,786 | (89,100 | ) | 32,264 | 569,144 | |||||||||||||
Loss
before reorganization items, net
|
(259,468 | ) | (307,667 | ) | (749,895 | ) | (2,547,201 | ) | (22,338,368 | ) | ||||||||||
Reorganization
items, net
|
147,885 | - | (111,243 | ) | - | (111,243 | ) | |||||||||||||
Net
loss
|
$ | (111,583 | ) | $ | (307,667 | ) | $ | (861,138 | ) | $ | (2,547,201 | ) | $ | (22,449,611 | ) | |||||
Net
loss per share:
|
||||||||||||||||||||
Basic
and diluted
|
$ | (0.00 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.10 | ) | ||||||||
Weighted-average
shares:
|
||||||||||||||||||||
Basic
and diluted
|
26,892,442 | 25,792,747 | 25,249,003 | 25,712,950 |
ARBIOS
SYSTEMS, INC.
|
(A
Development Stage Company)
|
CONDENSED
STATEMENTS OF CASH FLOWS
|
(Unaudited)
|
Predecessor
|
Predecessor
|
Predecessor
|
||||||||||
For
the nine months ended September 30,
|
Inception
to
|
|||||||||||
2009
|
2008
|
September
30, 2009
|
||||||||||
Cash
flows from operating activities:
|
||||||||||||
Net
loss
|
$ | (861,138 | ) | $ | (2,547,201 | ) | $ | (22,449,611 | ) | |||
Adjustments
to reconcile net loss to net cash
|
||||||||||||
used
in operating activities:
|
||||||||||||
Amortization
of debt discount
|
- | - | 244,795 | |||||||||
Depreciation
and amortization
|
2,757 | 32,190 | 338,794 | |||||||||
Patent
rights impairment
|
- | - | 91,694 | |||||||||
Issuance
of common stock, options and warrants for compensation
|
- | 441,055 | 4,071,460 | |||||||||
Issuance
of warrants for patent acquistion
|
- | - | 74,570 | |||||||||
Settlement
of accrued expense
|
- | - | 54,401 | |||||||||
Deferred
compensation costs
|
- | - | 319,553 | |||||||||
Loss
on disposition of fixed assets
|
3,120 | 2,207 | 8,157 | |||||||||
Loss
on disposition of investment
|
86,209 | - | 86,209 | |||||||||
Gain
on sale of HepatAssist program, net
|
- | - | (404,863 | ) | ||||||||
Non-cash
reorganization items, net
|
(226,103 | ) | - | (226,103 | ) | |||||||
Changes
in operating assets and liabilities:
|
||||||||||||
Prepaid
expenses
|
21,506 | 35,459 | - | |||||||||
Deferred
financing costs
|
- | 16,757 | - | |||||||||
Other
assets
|
750 | 68,686 | - | |||||||||
Accounts
payable
|
322,927 | (114,149 | ) | 516,971 | ||||||||
Accrued
expenses
|
(106,888 | ) | (97,367 | ) | 86,498 | |||||||
Other
liabilities
|
- | - | 64,695 | |||||||||
Contract
obligations
|
(150,000 | ) | (100,000 | ) | - | |||||||
Net
cash used in operating activities
|
(906,860 | ) | (2,262,363 | ) | (17,122,780 | ) | ||||||
Cash
flows from investing activities:
|
||||||||||||
Additions
of property and equipment
|
- | - | (149,467 | ) | ||||||||
Proceeds
from sale of fixed assets
|
300 | 4,175 | 4,476 | |||||||||
Proceeds
from sale of HepatAssist program
|
200,000 | - | 450,000 | |||||||||
Purchase
of short term investments
|
- | - | (21,866,787 | ) | ||||||||
Maturities
of short term investments
|
- | - | 21,866,787 | |||||||||
Net
cash provided from investing activities
|
200,300 | 4,175 | 305,009 | |||||||||
Cash
flows from financing activities:
|
||||||||||||
Proceeds
from issuance of convertible debt
|
- | - | 400,000 | |||||||||
Proceeds
from common stock option/warrant exercise
|
- | - | 67,900 | |||||||||
Net
proceeds from issuance of common stock and warrants
|
800,012 | - | 16,597,092 | |||||||||
Net
proceeds from issuance of preferred stock
|
- | - | 238,732 | |||||||||
Payments
on capital lease obligation, net
|
- | - | (21,815 | ) | ||||||||
Net
cash provided by financing activities
|
800,012 | - | 17,281,909 | |||||||||
Net
(decrease) increase in cash
|
93,452 | (2,258,188 | ) | 464,138 | ||||||||
Cash
at beginning of period
|
370,686 | 2,735,944 | - | |||||||||
Cash
at end of period
|
$ | 464,138 | $ | 477,756 | $ | 464,138 | ||||||
Supplemental
disclosures of non-cash financing activity
|
||||||||||||
Issuance
of securities for obligation related to finder's fees
|
$ | - | $ | - | $ | 47,500 |
The
accompanying notes are an integral part of these condensed financial
statements.
|
ARBIOS
SYSTEMS, INC.
|
(A
Development Stage Company)
|
CONDENSED
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
|
PERIOD
FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
|
(Unaudited)
|
Deficit
|
||||||||||||||||||||||||||||||||||||
Accumulated
|
||||||||||||||||||||||||||||||||||||
Additional
|
Receivable
|
During
the
|
||||||||||||||||||||||||||||||||||
Preferred
Stock
|
Common
Stock
|
Paid-In
|
for
Stock
|
Deferred
|
Development
|
|||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Issuance
|
Costs
|
Stage
|
Total
|
||||||||||||||||||||||||||||
Balance,
August 23,
|
||||||||||||||||||||||||||||||||||||
2000
(inception) restated
|
- | $ | - | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | ||||||||||||||||||||
for
effect of reverse merger
with
Historical Autographs U.S.A. Inc.
|
||||||||||||||||||||||||||||||||||||
Stock
issuance
|
||||||||||||||||||||||||||||||||||||
in
exchange for cash
|
5,000,000 | 50 | 4,950 | 5,000 | ||||||||||||||||||||||||||||||||
Net
loss
|
(9,454 | ) | (9,454 | ) | ||||||||||||||||||||||||||||||||
Balance,
December 31,
|
||||||||||||||||||||||||||||||||||||
2000,
as restated
|
- | - | 5,000,000 | 50 | 4,950 | - | - | (9,454 | ) | (4,454 | ) | |||||||||||||||||||||||||
Issuance
of junior preferred stock
|
||||||||||||||||||||||||||||||||||||
for
cash of $250,000 and in
|
||||||||||||||||||||||||||||||||||||
exchange
for $400,000 in patent rights,
|
||||||||||||||||||||||||||||||||||||
research
and development costs,
|
||||||||||||||||||||||||||||||||||||
and
employee loanout costs less
|
||||||||||||||||||||||||||||||||||||
issuance
expenses
|
||||||||||||||||||||||||||||||||||||
of
$11,268, June 29, 2001
|
681,818 | 7 | 958,278 | (343,553 | ) | 614,732 | ||||||||||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||||
for
patent rights and deferred research
|
||||||||||||||||||||||||||||||||||||
and
development costs
|
362,669 | 4 | 547,284 | 547,288 | ||||||||||||||||||||||||||||||||
Services
receivable
|
(550,000 | ) | (550,000 | ) | ||||||||||||||||||||||||||||||||
Deferred
employee
|
||||||||||||||||||||||||||||||||||||
loan-out
costs
|
||||||||||||||||||||||||||||||||||||
receivable
earned
|
82,888 | 82,888 | ||||||||||||||||||||||||||||||||||
Net
loss
|
(237,574 | ) | (237,574 | ) | ||||||||||||||||||||||||||||||||
Balance,
December 31, 2001
|
681,818 | 7 | 5,362,669 | 54 | 1,510,512 | - | (810,665 | ) | (247,028 | ) | 452,880 | |||||||||||||||||||||||||
The
accompanying notes are an integral part of these condensed financial
statements.
|
ARBIOS
SYSTEMS, INC.
|
(A
Development Stage Company)
|
CONDENSED
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
|
PERIOD
FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
|
(Unaudited)
|
Deficit
|
||||||||||||||||||||||||||||||||||||
Accumulated
|
||||||||||||||||||||||||||||||||||||
Additional
|
Receivable
|
During
the
|
||||||||||||||||||||||||||||||||||
Preferred
Stock
|
Common
Stock
|
Paid-In
|
for
Stock
|
Deferred
|
Development
|
|||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Issuance
|
Costs
|
Stage
|
Total
|
||||||||||||||||||||||||||||
Amendment
of December 31, 2001
|
||||||||||||||||||||||||||||||||||||
agreement
for the issuance of
|
||||||||||||||||||||||||||||||||||||
common
stock agreement in
|
||||||||||||||||||||||||||||||||||||
exchange
for research and
|
||||||||||||||||||||||||||||||||||||
development
services
|
(495,599 | ) | 550,000 | 54,401 | ||||||||||||||||||||||||||||||||
Deferred
employee loan out
|
||||||||||||||||||||||||||||||||||||
costs
receivable earned
|
171,776 | 171,776 | ||||||||||||||||||||||||||||||||||
Issuance
of common
|
||||||||||||||||||||||||||||||||||||
stock
for compensation
|
70,000 | 1 | 10,499 | 10,500 | ||||||||||||||||||||||||||||||||
Issuance
of common stock for cash
|
999,111 | 9 | 149,857 | 149,866 | ||||||||||||||||||||||||||||||||
Net
loss
|
(494,780 | ) | (494,780 | ) | ||||||||||||||||||||||||||||||||
Balance,
December 31, 2002
|
681,818 | 7 | 6,431,780 | 64 | 1,175,269 | - | (88,889 | ) | (741,808 | ) | 344,643 | |||||||||||||||||||||||||
Issuance
of common stock for cash
|
||||||||||||||||||||||||||||||||||||
less
issuance expense of $2,956
|
417,000 | 417 | 246,827 | 247,244 | ||||||||||||||||||||||||||||||||
Issuance
of common stock in private
|
||||||||||||||||||||||||||||||||||||
placement
for cash less
|
||||||||||||||||||||||||||||||||||||
issuance
expense of $519,230
|
4,000,000 | 4,000 | 3,476,770 | 3,480,770 | ||||||||||||||||||||||||||||||||
Issuance
of common stock
|
||||||||||||||||||||||||||||||||||||
for
convertible debenture less
|
||||||||||||||||||||||||||||||||||||
issuance
expense of $49,500
|
400,000 | 400 | 350,100 | 350,500 | ||||||||||||||||||||||||||||||||
Shares
issued in connection with
|
||||||||||||||||||||||||||||||||||||
acquisition
of Historical Autographs
|
||||||||||||||||||||||||||||||||||||
U.S.A.,
Inc. on October 30, 2003
|
1,220,000 | 8,263 | (8,263 | ) | - |
The
accompanying notes are an integral part of these condensed financial
statements.
|
ARBIOS
SYSTEMS, INC.
|
(A
Development Stage Company)
|
CONDENSED
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
|
PERIOD
FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
|
(Unaudited)
|
Deficit
|
||||||||||||||||||||||||||||||||||||
Accumulated
|
||||||||||||||||||||||||||||||||||||
Additional
|
Receivable
|
During
the
|
||||||||||||||||||||||||||||||||||
Preferred
Stock
|
Common
Stock
|
Paid-In
|
for
Stock
|
Deferred
|
Development
|
|||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Issuance
|
Costs
|
Stage
|
Total
|
||||||||||||||||||||||||||||
Value
of warrants and beneficial
|
||||||||||||||||||||||||||||||||||||
conversion
feature of bridge loan
|
244,795 | 244,795 | ||||||||||||||||||||||||||||||||||
Deferred
employee loan-out
|